G20: 19 Against 1 On Climate Change; Affordable Antimicrobials, Vaccines Planned 08/07/2017 by Monika Ermert for Intellectual Property Watch 2 Comments The G20 governments against some odds passed a joint communique today, but had to accept differences on climate and in one point also on free trade. The US delegation remained firm in their decision to withdraw from the Paris climate agreement and continue to support conventional energy resources, instead of renewable ones. German Chancellor Angela Merkel in her press conference explained that there was a clear division in the climate chapter of the G20 2017 Declaration.
G20 Reaches Agreement Against Terrorism, Appears To Target Encryption 07/07/2017 by Monika Ermert for Intellectual Property Watch 2 Comments At the G20 meeting in Hamburg today, the German hosts chose a retreat over the fight against terrorism as a warm-up, before turning to the controversial topics of free trade and climate change. Governments were very much in agreement when it comes to one thing: Internet platform providers must do more to fight radicalization and the use of the internet by terrorists.
G20: Security, Trade, Climate, Trump Diplomacy Overshadow Health, IT, Innovation 07/07/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment On the eve of the G20 meeting in Hamburg, Germany, German politicians described positions on free trade and climate as the most difficult issues. Expectations from civil society groups in the G20 results are modest at best and the 6 July protest march “Welcome to Hell” was cancelled after clashes between the police and parts of the protestors.
EU Parliament Adopts Marrakesh Treaty; Blind Union Prepared To Fight Publisher ‘Compensation’ 06/07/2017 by Monika Ermert for Intellectual Property Watch 4 Comments The European Parliament today with over 600 votes adopted the legal instruments to ratify the Marrakesh Treaty on access to reading material for the visually impaired. The treaty, adopted by the members of the World Intellectual Property Organization in 2013 and effective since last year, has been subject of controversies due to lobbying from publishers in the European Union, members of Parliament said today in Strasbourg before the vote. EU member states after today’s vote have one year to implement.
Novartis Loses Claim On Extension Of Data Exclusivity 28/06/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment In a decision today, the European Court of Justice in Luxembourg put an end to a complaint by Novartis Europharm Ltd against the European Commission over the terms for data exclusivity (C-629/15 P). Novartis had appealed an earlier decision by the European Court (the first instance) which had rejected the claims by the pharmaceutical company that it should be granted additional data exclusivity for Aclasta, developed from Novartis’ older drug Zometa. No way, the Court of Justice said today, upholding the judgment by the lower court that had found that Novartis’ interpretation of the rules would effectively allow the extension of data exclusivity for a drug forever.
Fierce Controversy Over Draft Hate Crime Legislation, New Surveillance Law In Germany 27/06/2017 by Monika Ermert for Intellectual Property Watch 2 Comments Just before the upcoming elections in September, the German government seems eager to push through legislation to rein in internet hate speech, fake news, and also legalise state hacks and police searches of computers and mobile phones against suspects of all kinds. Even at the United Nations and Organization for Security and Co-operation in Europe (OSCE) level the recent initiatives in Germany have resulted in some raised eyebrows. The draft hate speech law has also “made it to the alert list of the Council of Europe Platform to promote the protection of journalism.”
EU IP Enforcement Summit: Figures Grave, Reactions Slow 23/06/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment With figures now available for what intellectual property infringement is worth, the European Union copyright office made a call to action at its 2nd International IP Enforcement Summit in Berlin, which ended today. “Now that we know the facts, it is time to move to action and problem solving,” said Antonio Campinos, head of the EU IP Office (EUIPO).
Intermediaries At Centre Of Battle On EU IP Enforcement 22/06/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment BERLIN — The future of the European intellectual property enforcement framework is under heavy discussion at the second IP Enforcement Summit of the European Union Intellectual Property Office (EUIPO) in Berlin today.
EU Trade Politicians Consider Picking Up Pieces Of Trade Negotiations 02/06/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment European Union trade politicians and their counterparts from the United States need more time to consider next steps in their trade relations, EU trade Commissioner Cecilia Malmstroem said during a session with the trade committee of the European Parliament this week. At the same time, she reported that Trans-Pacific Partnership (TPP) and Trade in Services Agreement (TISA) negotiating partners have been turning to Europe to make headway. Meanwhile, former EU Justice Commissioner and member of the European Parliament, Viviane Reding, called for a counter-offensive to rising protectionism.
No Free Lunch, G20 Health Ministers Find At First Meeting 20/05/2017 by Monika Ermert for Intellectual Property Watch 3 Comments Group of 20 health ministers today finished their first joint table top exercise to simulate the outbreak of a new deadly viral pandemic in “Anycountry” and passed a seven-page final resolution on pandemic preparedness and antimicrobial resistance. Non-governmental experts and health organizations welcomed the first ever meeting of health ministers in the G20 format, but see a risk of framing the debate from a global North security perspective. And despite a call of urgency with regard to antimicrobial resistance, the G20 could not agree to include the de-linking of the cost of investment in R&D from the price of medical products.